• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Achieve Life Sciences Inc.

    2/27/24 3:32:52 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ACHV alert in real time by email
    SC 13G 1 d10982711_13g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

     

    Achieve Life Sciences, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

     

     

    004468500
    (CUSIP Number)

     

     

    November 15, 2022
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

     

    _____________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No 004468500    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Patrick J. Callahan III  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [  ]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
       2,167,439  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
       2,167,439  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,167,4391  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%  
             

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

     


    1 This figure includes 639,146 warrants beneficially owned by the Reporting Person each exercisable for 1 share of Common Stock, par value $0.001 per share.

     
     

     

    CUSIP No 004468500    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Patrick J. Callahan III Trust  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [  ]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Florida  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,067,439  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,067,439  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,067,4392  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.5%  
             

    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

     


    2 This figure includes 639,146 warrants beneficially owned by the Reporting Person each exercisable for 1 share of Common Stock, par value $0.001 per share.

     
     

     

    CUSIP No 004468500    

     

    Item 1. (a). Name of Issuer:  
           
        Achieve Life Sciences, Inc.  

     

      (b). Address of Issuer's Principal Executive Offices:  
           
       

    22722 29th Drive SE, Suite 100, Bothell, WA 98021

     

    1040 West Georgia Street, Suite 1030, Vancouver, British Columbia, Canada V6E 4H1

     

     

    Item 2. (a). Name of Person Filing:  
           
       

    Patrick J. Callahan III

    Patrick J. Callahan III Trust

     

     

      (b). Address of Principal Business Office, or if None, Residence:  
           
       

     

    Patrick J. Callahan III

    1189 Wilmette Avenue #216

    Wilmette, IL 60091

     

    Patrick J. Callahan III Trust

    c/o Patrick J. Callahan III

    1189 Wilmette Avenue #216

    Wilmette, IL 60091

     

     

     

      (c).

    Citizenship:

     

    Patrick J. Callahan III – United States citizen

    Patrick J. Callahan III Trust – Florida trust

       
       

     

      (d).   Title of Class of Securities:  
           
        Common Stock, par value $0.001 per share  

     

      (e). CUSIP Number:  
           
        004468500  

     

    Item 3.   If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).

     

      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

     

      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).

     

      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     
    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
       

    2,167,439 shares deemed beneficially owned by Patrick J. Callahan III

    2,067,439 shares deemed beneficially owned by Patrick J. Callahan III Trust

     

      (b)   Percent of class:
         
       

    9.9% deemed beneficially owned by Patrick J. Callahan III

    9.5% deemed beneficially owned by Patrick J. Callahan III Trust

     

         
      (c) Number of shares as to which Patrick J. Callahan III has:
         
        (i) Sole power to vote or to direct the vote 0  
             
        (ii)   Shared power to vote or to direct the vote 2,167,439  
             
        (iii) Sole power to dispose or to direct the disposition of 0  
             
        (iv)   Shared power to dispose or to direct the disposition of 2,167,439  
         
       

     

    Number of shares as to which Patrick J. Callahan III Trust has:

     
           
        (i) Sole power to vote or to direct the vote 0  
             
        (ii)   Shared power to vote or to direct the vote 2,067,439  
                         

        (iii) Sole power to dispose or to direct the disposition of 0  
             
        (iv)   Shared power to dispose or to direct the disposition of 2,067,439  

     

     
     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].

     

      N/A
     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

     

      N/A
       

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

      

     

    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

      N/A
       

     

    Item 8. Identification and Classification of Members of the Group.

      

     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

     

      N/A
       

     

    Item 9. Notice of Dissolution of Group.

     

     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

      N/A
         

     

    Item 10. Certification.

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      February 27, 2024
      (Date)
         

     

    Patrick J. Callahan III

     

     

    By: /s/ Patrick J. Callahan III
    Name: Patrick J. Callahan III

     

         
    Patrick J. Callahan III Trust  

    By: /s/ Patrick J. Callahan III

    Name: Patrick J. Callahan III

    Title: Trustee

     

         

     

     

       

     

     

     
     

    Exhibit A

    AGREEMENT

    The undersigned agree that this Schedule 13G dated February 27, 2024 relating to the Common Stock, par value $0.001 per share of Achieve Life Sciences, Inc. shall be filed on behalf of the undersigned.

     

      February 27, 2024
      (Date)
         

     

    Patrick J. Callahan III

     

     

    By: /s/ Patrick J. Callahan III
    Name: Patrick J. Callahan III

     

         
    Patrick J. Callahan III Trust  

    By: /s/ Patrick J. Callahan III

    Name: Patrick J. Callahan III

    Title: Trustee

     

     

     

       
         

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $ACHV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHV

    DatePrice TargetRatingAnalyst
    4/21/2026$13.00Buy
    Canaccord Genuity
    11/25/2025$19.00Mkt Outperform
    Citizens JMP
    8/21/2025$12.00Buy
    H.C. Wainwright
    11/14/2024$12.00Buy
    Rodman & Renshaw
    9/27/2024$20.00Strong Buy
    Raymond James
    5/10/2023$8.00 → $20.00Buy
    Maxim Group
    10/4/2021$25.00Buy
    Alliance Global Partners
    6/23/2021$23.00Outperform
    Oppenheimer
    More analyst ratings

    $ACHV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

    SEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ("Achieve" or the "Company") (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Jeffrey Farrow and Reid Waldman, MD have been appointed to its Board of Directors. "Jeffrey and Reid are exactly the kinds of operators you want around a board table when a company is preparing for its first launch," said Lucian Iancovici, MD, incoming Chairman of the Board of Directors of Achieve. "Jeffrey has lived the playbook of taking specialty companies from lat

    6/2/26 8:30:00 AM ET
    $ACHV
    $MANE
    $TARS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

    ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52 weeks of continuous exposure Nausea — a common barrier to treatment adherence with smoking cessation therapies — was reported in only 2.5% of participants over 52 weeks of continuous exposure¹ SEATTLE and VANCOUVER, British Columbia, May 19, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today

    5/19/26 2:15:00 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

    SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced three senior leadership appointments. Christopher Martin has joined the Company's Board of Directors. Mark Zappia has joined as Senior Vice President, Commercial, where he will spearhead the Company's commercial function. Jim Willis has joined as Vice President of Sales and Sales Enablement, where he will lead the field force. Mr. Martin most recently served as Chief Commercia

    5/12/26 7:05:00 AM ET
    $ACHV
    $EWTX
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACHV
    SEC Filings

    View All

    Achieve Life Sciences Inc. filed SEC Form 8-K: Leadership Update

    8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

    6/2/26 8:51:39 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form PRE 14A filed by Achieve Life Sciences Inc.

    PRE 14A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

    5/29/26 4:15:43 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form EFFECT filed by Achieve Life Sciences Inc.

    EFFECT - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

    5/22/26 12:15:16 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Oki Mark K bought $28,887 worth of shares (10,000 units at $2.89) (SEC Form 4)

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    3/19/25 4:38:43 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chieve Executive Officer Stewart Richard Alistair bought $28,598 worth of shares (10,000 units at $2.86), increasing direct ownership by 20% to 60,876 units (SEC Form 4)

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    3/19/25 4:32:22 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Stewart Richard Alistair bought $45,850 worth of shares (10,000 units at $4.58), increasing direct ownership by 35% to 38,501 units (SEC Form 4)

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    3/6/24 4:49:23 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Waldman Reid Alexander

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    6/2/26 4:13:36 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Director Farrow Jeffrey S

    4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    6/2/26 4:12:33 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    New insider Waldman Reid Alexander claimed no ownership of stock in the company (SEC Form 3)

    3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

    6/2/26 4:11:26 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Achieve Life Sciences with a new price target

    Canaccord Genuity initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $13.00

    4/21/26 7:30:27 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Citizens JMP initiated coverage on Achieve Life Sciences with a new price target

    Citizens JMP initiated coverage of Achieve Life Sciences with a rating of Mkt Outperform and set a new price target of $19.00

    11/25/25 8:38:19 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    H.C. Wainwright initiated coverage on Achieve Life Sciences with a new price target

    H.C. Wainwright initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $12.00

    8/21/25 8:16:03 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    Leadership Updates

    Live Leadership Updates

    View All

    Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

    Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors  New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of Milestone Warrants), Strengthen Achieve's Position to Execute Development and Launch of Cytisinicline, if Approved, as the First New Treatment for Nicotine Dependence in Two Decades SEATTLE and VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) today announced it has appointed Andrew D. Goldberg, MD, as Chief Executive Officer and as a member of the Board of Directors, effective following the closing of Achieve's recently announced financing

    4/16/26 8:57:06 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences Announces Up to $354 Million Private Placement

    $180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners, Paradigm BioCapital Advisors and Marshall Wace SEATTLE, Wash. and VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced it has entered into a securities purchase agreement with leading healthcare investors for a private placement of its securities for

    4/16/26 8:53:49 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

    SEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) --  Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced the appointment of Erik Atkisson as Chief Legal Officer. In his new role, Mr. Atkisson will oversee Achieve's legal strategy, corporate governance, compliance, and risk management. "Erik's extensive legal, regulatory and M&A background in the biopharmaceutical sector provides valuable experience as we advance cytisinicline through regulatory review and prepare for a potential laun

    10/20/25 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Achieve Life Sciences Inc.

    SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

    11/12/24 12:14:09 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Achieve Life Sciences Inc.

    SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

    11/4/24 10:59:37 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Achieve Life Sciences Inc. (Amendment)

    SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

    5/20/24 5:01:27 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACHV
    Financials

    Live finance-specific insights

    View All

    Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

    Closed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants Appoints New CEO and Expands Board of Directors Advances U.S.-based Manufacturing Transition & Partnership Conference Call Scheduled for 8:30 AM EDT Today, May 12, 2026 SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced financial results for the first quarter of 2026 and provided corporate highlights

    5/12/26 7:00:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026

    SEATTLE and VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its first quarter 2026 financial results and provide a corporate update on Tuesday, May 12, 2026, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q26 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or +1 201-689-7817 (International) and referencing conference ID 13759781. A webcast replay will be avail

    5/5/26 8:30:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced financial results for the fourth quarter and full year 2025 and provided updates on the cytisinicline development program, including the announcement of its partnership with Adare Pharma Solutions (Adare). "Achieve is full

    3/24/26 7:00:00 AM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care